Antibody repertoire: Embracing diversity

Science Translational Medicine

Volumn 3, Issue 93, 2011, Pages

  Pollard, Andrew J ^a   Hill, Adrian V S ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; MIFAMURTIDE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; VACCINE; MALARIA VACCINE; POLYSORBATE; PROTOZOON ANTIBODY; SQUALENE; TOLL LIKE RECEPTOR;

ANTIBACTERIAL ACTIVITY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; B LYMPHOCYTE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; ANIMAL; FEMALE; IMMUNOLOGY; MALE; NOTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; FEMALE; HUMANS; INFLUENZA VACCINES; MALARIA VACCINES; MALE; POLYSORBATES; SQUALENE; TOLL-LIKE RECEPTORS;

EID: 79960826697     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002694     Document Type: Review

References (15)

1. Centers for Disease Control and Prevention (CDC), Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015. MMWR Morb. Mortal. Wkly. Rep. 55, 511-515 (2006).
2. S. Khurana, N. Verma, J. W. Yewdell, A. K. Hilbert, F. Castellino, M. Lattanzi, G. Del Giudice, R. Rappuoli, H. Golding, MF59 adjuvant enhances diversity and affi nity of antibody-mediated immune response to pandemic infl uenza vaccines. Sci. Transl. Med. 3, 85ra48 (2011).
3. S. R. Wiley, V. S. Raman, A. Desbien, H. R. Bailor, R. Bhardwaj, A. R. Shakri, S. G. Reed, C. E. Chitnis, D. Carter, Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci. Transl. Med. 3, 93ra69 (2011).
4. M. Sadarangani, A. J. Pollard, Serogroup B meningococcal vaccines - An unfi nished story. Lancet Infect. Dis. 10, 112-124 (2010).
5. M. Recker, C. O. Buckee, A. Serazin, S. Kyes, R. Pinches, Z. Christodoulou, A. L. Springer, S. Gupta, C. I. Newbold, Antigenic variation in Plasmodium falciparum malaria involves a highly structured switching pattern. PLoS Pathog. 7, e1001306 (2011).
6. V. Kasprowicz, Y. H. Kang, M. Lucas, J. Schulze zur Wiesch, T. Kuntzen, V. Fleming, B. E. Nolan, S. Longworth, A. Berical, B. Bengsch, R. Thimme, L. Lewis-Ximenez, T. M. Allen, A. Y. Kim, P. Klenerman, G. M. Lauer, Hepatitis C virus (HCV) sequence variation induces an HCV-specifi c T-cell phenotype analogous to spontaneous resolution. J. Virol. 84, 1656-1663 (2010).
7. Y. Liu, J. McNevin, H. Zhao, D. M. Tebit, R. M. Troyer, M. McSweyn, A. K. Ghosh, D. Shriner, E. J. Arts, M. J. McElrath, J. I. Mullins, Evolution of human immunodefi ciency virus type 1 cytotoxic T-lymphocyte epitopes: Fitness-balanced escape. J. Virol. 81, 12179-12188 (2007).
8. A. Lange, N. M. Ferguson, Antigenic diversity, transmission mechanisms, and the evolution of pathogens. PLOS Comput. Biol. 5, e1000536 (2009).
9. S. P. Kasturi, I. Skountzou, R. A. Albrecht, D. Koutsonanos, T. Hua, H. I. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, F. Villinger, N. Murthy, J. Steel, J. Jacob, R. J. Hogan, A. García-Sastre, R. Compans, B. Pulendran, Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470, 543-547 (2011).
10. T. F. Schwarz, T. Horacek, M. Knuf, H. G. Damman, F. Roman, M. Dramé, P. Gillard, W. Jilg, Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27, 6284-6290 (2009).
11. C. S. Waddington, W. T. Walker, C. Oeser, A. Reiner, T. John, S. Wilkins, M. Casey, P. E. Eccleston, R. J. Allen, I. Okike, S. Ladhani, E. Sheasby, K. Hoschler, N. Andrews, P. Waight, A. C. Collinson, P. T. Heath, A. Finn, S. N. Faust, M. D. Snape, E. Miller, A. J. Pollard, Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 infl uenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
12. C. E. Chitnis, A. Sharma, Targeting the Plasmodium vivax Duff y-binding protein. Trends Parasitol. 24, 29-34 (2008).
13. D. F. Kelly, M. D. Snape, K. P. Perrett, E. A. Clutterbuck, S. Lewis, G. B. Rohner, M. Jones, L.-M. Yu, A. J. Pollard, Plasma and memory B-cell kinetics in infants following a primary schedule of CRM 197-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 127, 134-143 (2009).
14. G. J. Silverman, A. H. Lucas, Variable region diversity in human circulating antibodies specifi c for the capsular polysaccharide of Haemophilus infl uenzae type b. Preferential usage of two types of VH3 heavy chains. J. Clin. Invest. 88, 911-920 (1991).
15. Acknowledgments. A.J.P. and A.V.S.H. are Jenner Investigators and James Martin Senior Fellows at Oxford University and are supported by the NIHR Oxford Biomedical Research Centre. We thank S. J. Draper for comments on this Perspective.